Intravitreally Administered Soluble VEGF Receptor-1 Variant Tested as a Potential Gene Therapeutic for Diabetic Retinopathy

Figure 2

Animal experimental design and the in vivo efficacy of rAAV2-sVEGFRv-1. Experimental schematic (a). Immunohistochemistry performed on transverse section samples demonstrated human sVEGFRv-1 expression (red) in the retinas of the STZ-induced diabetic mouse model two months post intravitreal injection (b). Concentration of sVEGFRv-1 secreted into the vitreous humor as a result of effective retinal transduction was quantified by ELISA () with the vitreous humor sampled 10 days after rAAV2-sVEGFRv-1 administration (c). Scale bar: 50 μm; .

(a)

(b)

(c)